Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma, Colorectal Carcinoma, Malignant Solid Neoplasm, Prostate Carcinoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage I Prostate Cancer AJCC v8
Conditions
Brief summary
The Exercising Together trial is a single-blind, parallel group, randomized controlled trial comparing 3 arms: Arm 1 (experimental): Exercising Together where couples perform partnered exercise in a supervised, group setting versus two comparator conditions where survivors and partners perform exercise routines separately in either a supervised group setting (Arm 2) or unsupervised at home (Arm 3). All three arms will train for a 6-month period and then be followed 6 months later. Data will be collected at baseline, 3, 6 and 12 months.
Detailed description
PRIMARY OBJECTIVES: I. Determine the efficacy of Exercising Together on relationship quality (intimacy, communication and incongruence) in couples coping with prostate cancer (PC), breast cancer (BC), or colorectal cancer (CRC). II. Determine the efficacy of Exercising Together on the physical health (body composition, lipids, insulin resistance, blood pressure, inflammation, and physical function) and mental health (anxiety, depressive symptoms, fear of recurrence) of both the survivor and spouse/partner. III. Determine how long individual and couple-level benefits from Exercising Together last. EXPLORATORY OBJECTIVE: I. Identify the types of couples that benefit most from Exercising Together. OUTLINE: Study is a 3-group, 12-month (6 months of exercise training + 6-months follow-up) randomized trial. ARM I: Exercising Together Program: Couples perform partnered exercise over 1 hour, 2 days per week in a supervised, group setting. ARM II: Exercising Together Program: Survivors and spouses/partners perform exercise routines separately in a supervised group setting ARM III: Survivors and partners undergo 2 training sessions over 1 hour with an exercise trainer and then perform exercise routines over 1 hour 2 days per week separately unsupervised at home or a facility following an instructional digital video disc (DVD). The basic training program for all three study arms is a functional strength training program. Participants will use free weights (weighted vest, dumbbells, elastic bands) while performing lower body (chair rises, squats, lunges, stepups) and upper body (1-arm row, bench press, push-ups, triceps extension, bicep curls, shoulder raise) resistance exercise. Volume of resistance exercise, determined by intensity (weight, tailored to each individual) and duration (number of repetitions and sets), is gradually increased from low weight and high repetitions to more weight and fewer repetitions over the training period.
Interventions
BEHAVIORALExercise Intervention (supervised)
Complete supervised exercise
BEHAVIORALExercise Intervention (unsupervised)
Complete unsupervised exercise
OTHERInformational Intervention
Receive instructional DVD
OTHERQuestionnaire Administration
Ancillary studies
Sponsors
National Cancer Institute (NCI)
Oregon Health and Science University
OHSU Knight Cancer Institute
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)
Eligibility
Sex/Gender
ALL
Age
35 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
* SURVIVORS ONLY: * Histologically confirmed PC, BC or CRC without evidence of metastatic disease (confirmed by self-report on Health History Questionnaire. In the case a participant isn't able to confirm this criterion, a letter will be sent to his or her physician) * Three years or less from diagnosis date, by month and year, at time of enrollment (confirmed by self-report on Health History Questionnaire. In the case a participant isn't able to confirm this criterion, a letter will be sent to his or her physician) * Completed treatment (e.g., surgery, radiation and/or chemotherapy) \>= 6 weeks prior to enrollment. Concurrent adjuvant hormone therapy is permitted and must have been initiated \>= 6 weeks prior to enrollment. For prostate cancer, androgen deprivation therapy (ADT) may constitute primary treatment and must have been initiated \>= 6 weeks prior to enrollment. For breast cancer, hormone therapy may constitute primary treatment and must have been initiated \>= 6 weeks prior to enrollment. (confirmed by self-report on Health History Questionnaire. In the case a participant isn't able to confirm this criterion, a letter will be sent to his or her physician) * Co-residing with an intimate partner or spouse who is willing to participate (confirmed by self-report on Health History Questionnaire) * SURVIVORS AND SPOUSES/PARTNERS: * Underactive (\< 2 strength training sessions per week, lasting 30 minutes or more per session, at a moderate intensity in the last month) (confirmed by self-report on Health History Questionnaire or by discretion of the principal investigator)
Exclusion criteria
* SURVIVORS AND SPOUSES/PARTNERS * Cognitive difficulties that preclude answering the survey questions, participating in the exercise classes or performance tests, or providing informed consent as determined by the professional opinion of the principal investigator, Dr. Kerri Winters-Stone * A medical condition, movement or neurological disorder, or medication use that contraindicates participation in moderate intensity exercise. Specific contraindications include the following: declared pregnancy, poorly controlled diabetes, recent cardiac event, neuromuscular disease, untreated orthostatic hypertension, recent surgery, acute hernia, acute rheumatoid arthritis, severe memory disorders, severe balance disorder, inability to ambulate (use of an assistive device permitted), inability to stand for 3 minutes, severe hearing or vision problem. (For Survivor: Confirmed by physician clearance; For Spouse/Partner: must answer 'No' to American College of Sports Medicine pre-participation screening questions. If spouse/partner answers 'Yes' to either question they will be considered eligible upon physician clearance. Physician clearance may also be requested at the discretion of the principal investigator. For either: absence of pregnancy in persons who could possibly be pregnant but have not declared a pregnancy at screening, will be further screened with a pregnancy test administered at each testing visit.) * Knowingly unable to attend \> 75% of the intervention classes due to conflict with the designated time of day, days of the week, and/or location for the exercise class which they initially enrolled. (Confirmed by documentation in the Case Report Form titled CRF - Participant Contact Info\_Exercising Together) * Not fluent in English and therefore incapable of answering survey questions, participating in class, following directions during performance testing, and providing informed consent when English is the language used. (Confirmed by documentation in the Case Report Form titled CRF - Participant Contact Info\_Exercising Together or the professional opinion of the Principal Investigator, Dr. Kerri Winters-Stone.)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Dyadic Coping - Active Engagement | Baseline, 3, 6 and 12 months | Measured by the Active Engagement subscale from the Relationship Focused Coping Scale. The subscale assesses the degree with which couples practice active engagement by responding to five items on a Likert scale from 1 (never) to 5 (very often). Scores range from 5 to 25, with higher scores indicating more active engagement. Reported values reflect the estimated slope over 6-months. |
| Dyadic Coping - Protective Buffering | Baseline, 3, 6, and 12 months | Measured by the Protective Buffering Subscale from the Relationship Focused Coping Scale. Assesses the degree with which couples practice protective buffering by responding to six items using a Likert scale of 1 (never) to 5 (very often). Scores range from 6 to 30 with higher scores indicating more protective buffering. Reported values reflect the estimated slope over 6-months. |
| Emotional Intimacy | Baseline, 3, 6 and 12 months | Measured by the 7-item Dyadic Adjustment Scale (DAS) to assess each partner's satisfaction with their relationship by answering 7 questions on a 6-point scale ranging from 1(always agree) to 6 (always disagree). Scores range from 0-21 with higher scores indicating better dyadic adjustment. Reported values reflect the estimated slope over 6-months. |
| Physical Intimacy - Engagement in Sex | Baseline, 3, 6 and 12 months | Measured by the Physical Intimacy Behavior scale which asks participants the frequency that they engage in sexual behaviors answering two questions on a scale from 1 (none of the time) to 4 (most or all of the time). Scores range from 2 to 8 with higher scores indicating higher physical intimacy. |
| Physical Intimacy - Engagement in Affectionate Behaviors | Baseline, 3, 6, and 12-months | Measured by the Physical Intimacy Behavior scale which asks participants the frequency that they engage in affectionate behaviors answering four questions on a scale from 1 (none of the time) to 4 (most or all of the time). Scores range from 4 to 16 with higher scores indicating higher physical intimacy. |
| Concealment of Symptoms | Baseline, 3, 6 and 12 months | Measured by the Emotional-Intimacy Disruptive Behavior Scale. Patients report the extent to which they engage in 8 behaviors using a scale from 1 (rarely or none of the time) to 4 (most or all of the time). Scores range from 8-32 where higher scores indicate more concealment Reported values reflect the estimated slope over 6-months. |
| Pain Incongruence - Pain Intensity | Baseline, 3, 6 and 12 months | Measured by the degree of agreement (change or difference) between the survivor and partner ratings of the survivor's pain using the Brief Pain Inventory (BPI). This instrument has 2 subscales, pain intensity and pain interference. Values from items within each subscale are averaged together to yield scores 0-10. Low values indicate no pain and high values represent pain as bad as you can imagine. Reported values reflect the estimated slope over 6-months. |
| Pain Incongruence - Pain Interference | Baseline, 3, 6 and 12 months | Measured by the degree of agreement (difference) between the survivor and partner ratings of the survivor's pain using the Brief Pain Inventory (BPI). This instrument has 2 subscales, pain intensity and pain interference. Values from items within each subscale are averaged together to yield scores 0-10. Low values indicate no pain and high values represent pain as bad as you can imagine. Reported values reflect the estimated slope over 6-months. |
| Fatigue Incongruence | Baseline, 3, 6 and 12 months | Measured by the degree of agreement (difference) between the survivor and partner ratings of the survivor's fatigue in the past 7 days using the Functional Assessment in Chronic Illness Therapy (FACIT) fatigue questionnaire. This instrument has 13 items, and possible scores from 0 to 52. Low values indicate no fatigue, while high values indicate high fatigue. Reported values reflect the estimated slope over 6-months. |
| Perceived Physical Function Incongruence | Baseline, 3, 6 and 12 months | Measured by the degree of agreement (difference) between the survivor and partner ratings of the survivor's physical function in the past 4 weeks using the perceived physical function subscale of the SF-36 medical outcomes survey. Possible scores range from 0-100. Low scores indicate a high degree of limitation in performing physical activities, whereas high scores represent no limitations in performing physical activities due to health. Reported values reflect the estimated slope over 6-months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Quality of Life (QOL): QLQ-C30 - Physical Functioning | Baseline, 3, 6 and 12 months | Measures QOL in cancer patients including subscales of physical functioning. Scores range from 0-100 for overall QOL and subscales where higher scores indicate better functioning. |
| Quality of Life (QOL): QLQ-C30 - Emotional Functioning | Baseline, 3, 6, 12 months | Measures QOL in cancer patients including subscales of emotional functioning. Scores range from 0-100 for overall QOL and subscales where higher scores indicate better functioning. |
| Quality of Life (QOL): SF-36 Physical Function Subscale | Baseline, 3, 6 and 12 months | The SF-36 measures quality of life using 8 subscales: perceived physical function, role limitations due to physical problems, social functioning, bodily pain, general mental health, role limitations due to emotional problems, vitality, and general health perceptions. All subscales have possible scores from 0-100, with items from each subscale averaged together. Low scores indicate worse physical functioning, while higher scores indicate better physical functioning. |
| Body Composition - Bone-free Lean Mass | Baseline, 3, 6 and 12 months | Measured by bone-free lean (kg) for the whole body determined from a whole body dual energy x-ray absorptiometry (DXA) (Hologic-QDR Discovery Wi; APEX software, v.4.02) scan. |
| Anxiety: PROMIS Anxiety Short Form | Baseline, 3, 6 and 12 months | Measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety short form 8a, using T score, standardized to mean = 50, SD = 10. Possible range for this short form is 37.1-83.1. Higher T scores reflect higher anxiety. Reported values reflect the estimated slope over 6-months. |
| Fear of Recurrence | Baseline, 3, 6 and 12 months | Measured by the Fear of Recurrence scale to assess the amount of concern survivors have about their cancer returning in the future. Participants respond to 22 questions ranging from 1 (strongly agree) to 5 (strongly disagree). The possible range is 22-110. Higher scores reflect higher fear. Reported values reflect the estimated slope over 6-months. |
| Depressive Symptoms: CES-D | Baseline, 3, 6 and 12 months | Measured by the Center for Epidemiological Studies-Depression (CES-D) scale to determine the degree of depressive symptoms. Scores range from 0-60, with higher scores indicating more symptoms that occur at higher frequencies. |
| Body Composition - Fat Mass | Baseline, 3, 6, and 12 months | Measured by fat mas (kg) for the whole body determined from a whole body dual x-ray absorptiometry (DXA) (Hologic-QDR Discovery Wi; APEX software, v.4.02) scan. |
| Cardiovascular Health: Serum Cholesterol | Baseline, 3, 6 and 12 months | Measured by serum fasting total cholesterol. |
| Cardiovascular Health: Serum Triglycerides | Baseline, 3, 6, and 12 months | Measured by serum triglycerides. |
| Cardiovascular Health: Insulin Resistance | Baseline, 3, 6 and 12 months | Measured by Homeostasis Model Assessment - Insulin Resistance (HOMA-IR) - used to assess insulin sensitivity and predict the risk of type 2 diabetes and other metabolic disorders. Calculated as the product of glucose and insulin, obtained from a fasting blood sample, divided by a constant, 405. Scores generally range from 0.5 to 2.5, with lower scores indicating better insulin sensitivity and higher scores suggesting higher insulin resistance. A HOMA-IR score of 1.0 or less is considered optimal, while scores above 2.9 may indicate significant insulin resistance. Reported values reflect the estimated slope over 6-months. (Glucose mg/dL \* insulin uIU/ml) / 405 |
| Cardiovascular Health: Resting Systolic Blood Pressure | Baseline, 3, 6 and 12 months | Measured by the average of three consecutive resting blood pressure measurements (systolic and diastolic pressures). |
| Cardiovascular Health: Resting Diastolic Blood Pressure | Baseline, 3, 6, 12 months | Measured by the average of three consecutive resting blood pressure measurements (systolic and diastolic pressures). |
| Inflammation-hsCRP | Baseline, 3, 6 and 12 months | Measured by serum levels of high sensitivity C-reactive protein (hsCRP) obtained from a fasting blood sample. |
| Inflammation-TNF Alpha | Baseline, 3, 6 and 12 months | Measured by serum levels of tumor necrosis factor alpha (TNF alpha) obtained from a fasting blood sample. |
| Objective Physical Function | Baseline, 3, 6 and 12 months | Measured by the Physical Performance Battery (PPB) to determine a person's ability to perform daily tasks independently. The PPB consists of 3 timed tests: 5 repeated chair stands, standing balance, and gait speed over 4 meters. Each test is scored 0 (unable) to 4 (completes without difficulty), based on quartiles of performance, then scores are summed. The possible range of scores is 0-12. |
Countries
United States
Participant flow
Recruitment details
Community-dwelling couples were recruited between January 2019 and October 2022. The first couple was enrolled on January 18, 2019 and the last was couple was enrolled on October 26, 2022.
Pre-assignment details
Of 269 consented couples, 248 couples (496 individuals: 248 survivors + 248 partners) met inclusion criteria and were randomized to an intervention group.
Participants by arm
| Arm | Count |
|---|---|
| Arm I (Supervised Exercise Together) Couples perform partnered exercise over 1 hour, 2 days per week in a supervised, group setting remotely for 6 months.
Exercise Intervention: Complete supervised exercise
Questionnaire Administration: Ancillary studies | 164 |
| Arm II (Supervised Exercise Separately) Survivors and partners perform exercise routines over 1 hour, 2 days per week separately in a supervised group setting remotely for 6 months.
Exercise Intervention: Complete supervised exercise
Questionnaire Administration: Ancillary studies | 170 |
| Arm III (Unsupervised Exercise Separately) Survivors and partners undergo 2 training sessions remotely over 1 hour with an exercise trainer and then perform exercise routines over 1 hour, 2 days per week unsupervised at home or a facility following an instructional DVD.
Exercise Intervention: Complete unsupervised exercise
Informational Intervention: Receive instructional DVD
Questionnaire Administration: Ancillary studies | 162 |
| Total | 496 |
Baseline characteristics
| Characteristic | Arm I (Supervised Exercise Together) | Arm II (Supervised Exercise Separately) | Arm III (Unsupervised Exercise Separately) | Total |
|---|---|---|---|---|
| Age, Continuous | 64.8 years STANDARD_DEVIATION 9.46 | 62.7 years STANDARD_DEVIATION 10.7 | 62.6 years STANDARD_DEVIATION 65.5 | 63.4 years STANDARD_DEVIATION 10.1 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 1 Participants | 3 Participants | 7 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 78 Participants | 82 Participants | 78 Participants | 238 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 3 Participants | 5 Participants | 9 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants | 0 Participants | 1 Participants | 3 Participants |
| Race (NIH/OMB) More than one race | 2 Participants | 4 Participants | 3 Participants | 7 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 1 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 3 Participants | 4 Participants |
| Race (NIH/OMB) White | 77 Participants | 75 Participants | 72 Participants | 223 Participants |
| Region of Enrollment United States | 82 Participants | 85 Participants | 81 Participants | 248 Participants |
| Sex: Female, Male Female | 41 Participants | 45 Participants | 46 Participants | 133 Participants |
| Sex: Female, Male Male | 41 Participants | 42 Participants | 35 Participants | 115 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 164 | 0 / 170 | 0 / 162 |
| other Total, other adverse events | 9 / 164 | 6 / 170 | 3 / 162 |
| serious Total, serious adverse events | 4 / 164 | 2 / 170 | 1 / 162 |
Outcome results
Primary
Concealment of Symptoms
Measured by the Emotional-Intimacy Disruptive Behavior Scale. Patients report the extent to which they engage in 8 behaviors using a scale from 1 (rarely or none of the time) to 4 (most or all of the time). Scores range from 8-32 where higher scores indicate more concealment Reported values reflect the estimated slope over 6-months.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Concealment of Symptoms | Survivor: 6mo-12mo | -.23 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Concealment of Symptoms | Survivor: Baseline-6mo | -.24 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Concealment of Symptoms | Partner: 6mo-12mo | .63 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Concealment of Symptoms | Partner: Baseline-6mo | -.33 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Concealment of Symptoms | Survivor: Baseline-6mo | .07 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Concealment of Symptoms | Partner: 6mo-12mo | -.23 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Concealment of Symptoms | Partner: Baseline-6mo | -.44 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Concealment of Symptoms | Survivor: 6mo-12mo | -.18 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Concealment of Symptoms | Partner: 6mo-12mo | -.11 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Concealment of Symptoms | Partner: Baseline-6mo | -.70 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Concealment of Symptoms | Survivor: 6mo-12mo | .53 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Concealment of Symptoms | Survivor: Baseline-6mo | -.82 Score on a scale per 6 months |
Primary
Dyadic Coping - Active Engagement
Measured by the Active Engagement subscale from the Relationship Focused Coping Scale. The subscale assesses the degree with which couples practice active engagement by responding to five items on a Likert scale from 1 (never) to 5 (very often). Scores range from 5 to 25, with higher scores indicating more active engagement. Reported values reflect the estimated slope over 6-months.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Dyadic Coping - Active Engagement | Survivor: Baseline-6mo | -0.45 score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Dyadic Coping - Active Engagement | Survivor: 6mo-12mo | -0.35 score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Dyadic Coping - Active Engagement | Partner: 6mo-12mo | -0.52 score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Dyadic Coping - Active Engagement | Partner: Baseline-6mo | 0.05 score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Dyadic Coping - Active Engagement | Survivor: 6mo-12mo | -0.61 score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Dyadic Coping - Active Engagement | Survivor: Baseline-6mo | 0.81 score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Dyadic Coping - Active Engagement | Partner: Baseline-6mo | -0.08 score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Dyadic Coping - Active Engagement | Partner: 6mo-12mo | -0.14 score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Dyadic Coping - Active Engagement | Partner: 6mo-12mo | -0.35 score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Dyadic Coping - Active Engagement | Partner: Baseline-6mo | -0.91 score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Dyadic Coping - Active Engagement | Survivor: Baseline-6mo | 0.07 score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Dyadic Coping - Active Engagement | Survivor: 6mo-12mo | -0.08 score on a scale per 6 months |
Primary
Dyadic Coping - Protective Buffering
Measured by the Protective Buffering Subscale from the Relationship Focused Coping Scale. Assesses the degree with which couples practice protective buffering by responding to six items using a Likert scale of 1 (never) to 5 (very often). Scores range from 6 to 30 with higher scores indicating more protective buffering. Reported values reflect the estimated slope over 6-months.
Time frame: Baseline, 3, 6, and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Dyadic Coping - Protective Buffering | Partner: 6mo-12mo | -0.04 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Dyadic Coping - Protective Buffering | Survivor: 6mo-12mo | -0.21 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Dyadic Coping - Protective Buffering | Partner: Baseline-6mo | 0.36 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Dyadic Coping - Protective Buffering | Survivor: Baseline-6mo | -0.48 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Dyadic Coping - Protective Buffering | Survivor: Baseline-6mo | -0.18 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Dyadic Coping - Protective Buffering | Partner: Baseline-6mo | -0.09 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Dyadic Coping - Protective Buffering | Survivor: 6mo-12mo | -0.46 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Dyadic Coping - Protective Buffering | Partner: 6mo-12mo | -0.20 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Dyadic Coping - Protective Buffering | Survivor: 6mo-12mo | -0.57 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Dyadic Coping - Protective Buffering | Partner: 6mo-12mo | -0.27 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Dyadic Coping - Protective Buffering | Survivor: Baseline-6mo | -0.13 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Dyadic Coping - Protective Buffering | Partner: Baseline-6mo | 0.36 Score on a scale per 6 months |
Primary
Emotional Intimacy
Measured by the 7-item Dyadic Adjustment Scale (DAS) to assess each partner's satisfaction with their relationship by answering 7 questions on a 6-point scale ranging from 1(always agree) to 6 (always disagree). Scores range from 0-21 with higher scores indicating better dyadic adjustment. Reported values reflect the estimated slope over 6-months.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Emotional Intimacy | Partner: Baseline-6mo | .98 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Emotional Intimacy | Survivor: Baseline-6mo | 3.37 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Emotional Intimacy | Partner: 6mo-12mo | -2.63 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Emotional Intimacy | Survivor: 6mo-12mo | -2.87 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Emotional Intimacy | Partner: Baseline-6mo | 1.90 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Emotional Intimacy | Survivor: 6mo-12mo | -2.30 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Emotional Intimacy | Survivor: Baseline-6mo | 2.61 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Emotional Intimacy | Partner: 6mo-12mo | -.43 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Emotional Intimacy | Partner: 6mo-12mo | 1.96 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Emotional Intimacy | Survivor: Baseline-6mo | 2.97 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Emotional Intimacy | Survivor: 6mo-12mo | -1.33 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Emotional Intimacy | Partner: Baseline-6mo | -.99 Score on a scale per 6 months |
Primary
Fatigue Incongruence
Measured by the degree of agreement (difference) between the survivor and partner ratings of the survivor's fatigue in the past 7 days using the Functional Assessment in Chronic Illness Therapy (FACIT) fatigue questionnaire. This instrument has 13 items, and possible scores from 0 to 52. Low values indicate no fatigue, while high values indicate high fatigue. Reported values reflect the estimated slope over 6-months.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Fatigue Incongruence | Baseline-6mo | 1.02 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Fatigue Incongruence | 6mo-12mo | -1.20 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Fatigue Incongruence | Baseline-6mo | -1.24 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Fatigue Incongruence | 6mo-12mo | -.03 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Fatigue Incongruence | Baseline-6mo | -.41 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Fatigue Incongruence | 6mo-12mo | -.67 Score on a scale per 6 months |
Primary
Pain Incongruence - Pain Intensity
Measured by the degree of agreement (change or difference) between the survivor and partner ratings of the survivor's pain using the Brief Pain Inventory (BPI). This instrument has 2 subscales, pain intensity and pain interference. Values from items within each subscale are averaged together to yield scores 0-10. Low values indicate no pain and high values represent pain as bad as you can imagine. Reported values reflect the estimated slope over 6-months.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Pain Incongruence - Pain Intensity | Baseline-6mo | .17 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Pain Incongruence - Pain Intensity | 6mo-12mo | -.08 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Pain Incongruence - Pain Intensity | Baseline-6mo | .08 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Pain Incongruence - Pain Intensity | 6mo-12mo | .16 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Pain Incongruence - Pain Intensity | Baseline-6mo | .16 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Pain Incongruence - Pain Intensity | 6mo-12mo | .16 Score on a scale per 6 months |
Primary
Pain Incongruence - Pain Interference
Measured by the degree of agreement (difference) between the survivor and partner ratings of the survivor's pain using the Brief Pain Inventory (BPI). This instrument has 2 subscales, pain intensity and pain interference. Values from items within each subscale are averaged together to yield scores 0-10. Low values indicate no pain and high values represent pain as bad as you can imagine. Reported values reflect the estimated slope over 6-months.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Pain Incongruence - Pain Interference | Baseline-6mo | -.38 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Pain Incongruence - Pain Interference | 6mo-12mo | .27 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Pain Incongruence - Pain Interference | 6mo-12mo | -.09 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Pain Incongruence - Pain Interference | Baseline-6mo | .01 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Pain Incongruence - Pain Interference | Baseline-6mo | -.05 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Pain Incongruence - Pain Interference | 6mo-12mo | .16 Score on a scale per 6 months |
Primary
Perceived Physical Function Incongruence
Measured by the degree of agreement (difference) between the survivor and partner ratings of the survivor's physical function in the past 4 weeks using the perceived physical function subscale of the SF-36 medical outcomes survey. Possible scores range from 0-100. Low scores indicate a high degree of limitation in performing physical activities, whereas high scores represent no limitations in performing physical activities due to health. Reported values reflect the estimated slope over 6-months.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Perceived Physical Function Incongruence | Baseline-6mo | .41 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Perceived Physical Function Incongruence | 6mo-12mo | 1.33 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Perceived Physical Function Incongruence | 6mo-12mo | .62 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Perceived Physical Function Incongruence | Baseline-6mo | -.66 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Perceived Physical Function Incongruence | Baseline-6mo | -.83 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Perceived Physical Function Incongruence | 6mo-12mo | 1.29 Score on a scale per 6 months |
Primary
Physical Intimacy - Engagement in Affectionate Behaviors
Measured by the Physical Intimacy Behavior scale which asks participants the frequency that they engage in affectionate behaviors answering four questions on a scale from 1 (none of the time) to 4 (most or all of the time). Scores range from 4 to 16 with higher scores indicating higher physical intimacy.
Time frame: Baseline, 3, 6, and 12-months
Population: This measure had a significant amount of missing data (due to the sensitivity of the questions) so the total sample size is reduced.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Physical Intimacy - Engagement in Affectionate Behaviors | Partner: Baseline-6mo | 0.30 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Physical Intimacy - Engagement in Affectionate Behaviors | Survivor: 6mo-12mo | -0.04 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Physical Intimacy - Engagement in Affectionate Behaviors | Survivor: Baseline-6mo | 0.37 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Physical Intimacy - Engagement in Affectionate Behaviors | Partner: 6mo-12mo | -0.37 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Physical Intimacy - Engagement in Affectionate Behaviors | Survivor: 6mo-12mo | 0.02 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Physical Intimacy - Engagement in Affectionate Behaviors | Survivor: Baseline-6mo | 0.08 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Physical Intimacy - Engagement in Affectionate Behaviors | Partner: Baseline-6mo | 0.29 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Physical Intimacy - Engagement in Affectionate Behaviors | Partner: 6mo-12mo | -0.18 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Physical Intimacy - Engagement in Affectionate Behaviors | Partner: 6mo-12mo | -0.15 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Physical Intimacy - Engagement in Affectionate Behaviors | Partner: Baseline-6mo | 0.23 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Physical Intimacy - Engagement in Affectionate Behaviors | Survivor: Baseline-6mo | 0.19 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Physical Intimacy - Engagement in Affectionate Behaviors | Survivor: 6mo-12mo | 0.15 Score on a scale per 6 months |
Primary
Physical Intimacy - Engagement in Sex
Measured by the Physical Intimacy Behavior scale which asks participants the frequency that they engage in sexual behaviors answering two questions on a scale from 1 (none of the time) to 4 (most or all of the time). Scores range from 2 to 8 with higher scores indicating higher physical intimacy.
Time frame: Baseline, 3, 6 and 12 months
Population: This measure had a significant amount of missing data (due to the sensitivity of the questions) so the total sample size is reduced.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Physical Intimacy - Engagement in Sex | Partner: Baseline-6mo | 0.10 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Physical Intimacy - Engagement in Sex | Partner: 6mo-12mo | -0.12 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Physical Intimacy - Engagement in Sex | Survivor: Baseline-6mo | 0.08 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Physical Intimacy - Engagement in Sex | Survivor: 6mo-12mo | -0.02 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Physical Intimacy - Engagement in Sex | Partner: Baseline-6mo | 0.16 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Physical Intimacy - Engagement in Sex | Survivor: 6mo-12mo | 0.19 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Physical Intimacy - Engagement in Sex | Partner: 6mo-12mo | -0.23 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Physical Intimacy - Engagement in Sex | Survivor: Baseline-6mo | -0.04 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Physical Intimacy - Engagement in Sex | Partner: 6mo-12mo | 0.03 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Physical Intimacy - Engagement in Sex | Survivor: Baseline-6mo | -0.07 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Physical Intimacy - Engagement in Sex | Survivor: 6mo-12mo | -0.02 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Physical Intimacy - Engagement in Sex | Partner: Baseline-6mo | -0.08 Score on a scale per 6 months |
Secondary
Anxiety: PROMIS Anxiety Short Form
Measured by the Patient-Reported Outcomes Measurement Information System (PROMIS) anxiety short form 8a, using T score, standardized to mean = 50, SD = 10. Possible range for this short form is 37.1-83.1. Higher T scores reflect higher anxiety. Reported values reflect the estimated slope over 6-months.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Anxiety: PROMIS Anxiety Short Form | Survivor: Baseline-6mo | -1.93 T score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Anxiety: PROMIS Anxiety Short Form | Survivor: 6mo-12mo | -0.30 T score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Anxiety: PROMIS Anxiety Short Form | Partner: Baseline-6mo | -1.71 T score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Anxiety: PROMIS Anxiety Short Form | Partner: 6mo-12mo | 1.17 T score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Anxiety: PROMIS Anxiety Short Form | Partner: 6mo-12mo | -0.16 T score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Anxiety: PROMIS Anxiety Short Form | Survivor: Baseline-6mo | -2.23 T score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Anxiety: PROMIS Anxiety Short Form | Partner: Baseline-6mo | -0.94 T score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Anxiety: PROMIS Anxiety Short Form | Survivor: 6mo-12mo | 0.42 T score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Anxiety: PROMIS Anxiety Short Form | Partner: 6mo-12mo | -1.25 T score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Anxiety: PROMIS Anxiety Short Form | Survivor: 6mo-12mo | -0.23 T score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Anxiety: PROMIS Anxiety Short Form | Partner: Baseline-6mo | -1.40 T score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Anxiety: PROMIS Anxiety Short Form | Survivor: Baseline-6mo | -1.18 T score on a scale per 6 months |
Secondary
Body Composition - Bone-free Lean Mass
Measured by bone-free lean (kg) for the whole body determined from a whole body dual energy x-ray absorptiometry (DXA) (Hologic-QDR Discovery Wi; APEX software, v.4.02) scan.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Body Composition - Bone-free Lean Mass | Partner: 6mo-12mo | -1.43 kg per 6 months |
| Arm I (Supervised Exercise Together) | Body Composition - Bone-free Lean Mass | Survivor: Baseline-6mo | 3.38 kg per 6 months |
| Arm I (Supervised Exercise Together) | Body Composition - Bone-free Lean Mass | Partner: Baseline-6mo | 3.20 kg per 6 months |
| Arm I (Supervised Exercise Together) | Body Composition - Bone-free Lean Mass | Survivor: 6mo-12mo | -0.89 kg per 6 months |
| Arm II (Supervised Exercise Separately) | Body Composition - Bone-free Lean Mass | Partner: Baseline-6mo | 3.32 kg per 6 months |
| Arm II (Supervised Exercise Separately) | Body Composition - Bone-free Lean Mass | Partner: 6mo-12mo | -1.03 kg per 6 months |
| Arm II (Supervised Exercise Separately) | Body Composition - Bone-free Lean Mass | Survivor: 6mo-12mo | -0.60 kg per 6 months |
| Arm II (Supervised Exercise Separately) | Body Composition - Bone-free Lean Mass | Survivor: Baseline-6mo | 3.19 kg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Body Composition - Bone-free Lean Mass | Partner: 6mo-12mo | -1.05 kg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Body Composition - Bone-free Lean Mass | Survivor: 6mo-12mo | -1.04 kg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Body Composition - Bone-free Lean Mass | Partner: Baseline-6mo | 3.17 kg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Body Composition - Bone-free Lean Mass | Survivor: Baseline-6mo | 3.19 kg per 6 months |
Secondary
Body Composition - Fat Mass
Measured by fat mas (kg) for the whole body determined from a whole body dual x-ray absorptiometry (DXA) (Hologic-QDR Discovery Wi; APEX software, v.4.02) scan.
Time frame: Baseline, 3, 6, and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Body Composition - Fat Mass | Survivor: Baseline-6mo | -3.32 kg per 6 months |
| Arm I (Supervised Exercise Together) | Body Composition - Fat Mass | Survivor: 6mo-12mo | 1.38 kg per 6 months |
| Arm I (Supervised Exercise Together) | Body Composition - Fat Mass | Partner: Baseline-6mo | -3.63 kg per 6 months |
| Arm I (Supervised Exercise Together) | Body Composition - Fat Mass | Partner: 6mo-12mo | 0.22 kg per 6 months |
| Arm II (Supervised Exercise Separately) | Body Composition - Fat Mass | Partner: 6mo-12mo | 0.87 kg per 6 months |
| Arm II (Supervised Exercise Separately) | Body Composition - Fat Mass | Survivor: Baseline-6mo | -3.50 kg per 6 months |
| Arm II (Supervised Exercise Separately) | Body Composition - Fat Mass | Partner: Baseline-6mo | -3.36 kg per 6 months |
| Arm II (Supervised Exercise Separately) | Body Composition - Fat Mass | Survivor: 6mo-12mo | 1.05 kg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Body Composition - Fat Mass | Partner: 6mo-12mo | 0.25 kg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Body Composition - Fat Mass | Survivor: 6mo-12mo | 0.53 kg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Body Composition - Fat Mass | Partner: Baseline-6mo | -3.16 kg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Body Composition - Fat Mass | Survivor: Baseline-6mo | -2.77 kg per 6 months |
Secondary
Cardiovascular Health: Insulin Resistance
Measured by Homeostasis Model Assessment - Insulin Resistance (HOMA-IR) - used to assess insulin sensitivity and predict the risk of type 2 diabetes and other metabolic disorders. Calculated as the product of glucose and insulin, obtained from a fasting blood sample, divided by a constant, 405. Scores generally range from 0.5 to 2.5, with lower scores indicating better insulin sensitivity and higher scores suggesting higher insulin resistance. A HOMA-IR score of 1.0 or less is considered optimal, while scores above 2.9 may indicate significant insulin resistance. Reported values reflect the estimated slope over 6-months. (Glucose mg/dL \* insulin uIU/ml) / 405
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Insulin Resistance | Survivor: Baseline-6mo | -0.06 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Insulin Resistance | Partner: 6mo-12mo | -0.01 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Insulin Resistance | Survivor: 6mo-12mo | -0.05 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Insulin Resistance | Partner: Baseline-6mo | 0.01 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Insulin Resistance | Partner: Baseline-6mo | -0.13 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Insulin Resistance | Survivor: 6mo-12mo | 0.01 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Insulin Resistance | Partner: 6mo-12mo | 0.13 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Insulin Resistance | Survivor: Baseline-6mo | -0.02 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Insulin Resistance | Partner: 6mo-12mo | -0.08 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Insulin Resistance | Survivor: 6mo-12mo | -0.03 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Insulin Resistance | Partner: Baseline-6mo | 0.03 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Insulin Resistance | Survivor: Baseline-6mo | -0.01 Score on a scale per 6 months |
Secondary
Cardiovascular Health: Resting Diastolic Blood Pressure
Measured by the average of three consecutive resting blood pressure measurements (systolic and diastolic pressures).
Time frame: Baseline, 3, 6, 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Resting Diastolic Blood Pressure | Survivor: Baseline-6mo | -2.07 mmHg per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Resting Diastolic Blood Pressure | Partner: Baseline-6mo | -3.26 mmHg per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Resting Diastolic Blood Pressure | Survivor: 6mo-12mo | 1.42 mmHg per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Resting Diastolic Blood Pressure | Partner: 6mo-12mo | -0.58 mmHg per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Resting Diastolic Blood Pressure | Survivor: Baseline-6mo | -4.10 mmHg per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Resting Diastolic Blood Pressure | Partner: 6mo-12mo | -1.30 mmHg per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Resting Diastolic Blood Pressure | Partner: Baseline-6mo | -4.93 mmHg per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Resting Diastolic Blood Pressure | Survivor: 6mo-12mo | 1.14 mmHg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Resting Diastolic Blood Pressure | Partner: 6mo-12mo | -2.26 mmHg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Resting Diastolic Blood Pressure | Partner: Baseline-6mo | -2.50 mmHg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Resting Diastolic Blood Pressure | Survivor: 6mo-12mo | 1.48 mmHg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Resting Diastolic Blood Pressure | Survivor: Baseline-6mo | -2.34 mmHg per 6 months |
Secondary
Cardiovascular Health: Resting Systolic Blood Pressure
Measured by the average of three consecutive resting blood pressure measurements (systolic and diastolic pressures).
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Resting Systolic Blood Pressure | Survivor: Baseline-6mo | -4.91 mmHg per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Resting Systolic Blood Pressure | Survivor: 6mo-12mo | 0.83 mmHg per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Resting Systolic Blood Pressure | Partner: Baseline-6mo | -5.92 mmHg per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Resting Systolic Blood Pressure | Partner: 6mo-12mo | -0.41 mmHg per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Resting Systolic Blood Pressure | Partner: 6mo-12mo | -7.02 mmHg per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Resting Systolic Blood Pressure | Survivor: Baseline-6mo | -5.50 mmHg per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Resting Systolic Blood Pressure | Partner: Baseline-6mo | -7.58 mmHg per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Resting Systolic Blood Pressure | Survivor: 6mo-12mo | 3.46 mmHg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Resting Systolic Blood Pressure | Partner: 6mo-12mo | -1.56 mmHg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Resting Systolic Blood Pressure | Survivor: 6mo-12mo | 2.38 mmHg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Resting Systolic Blood Pressure | Partner: Baseline-6mo | -7.93 mmHg per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Resting Systolic Blood Pressure | Survivor: Baseline-6mo | -3.34 mmHg per 6 months |
Secondary
Cardiovascular Health: Serum Cholesterol
Measured by serum fasting total cholesterol.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Serum Cholesterol | Survivor: Baseline-6mo | -4.23 mg/dL per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Serum Cholesterol | Survivor: 6mo-12mo | 3.77 mg/dL per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Serum Cholesterol | Partner: Baseline-6mo | -2.89 mg/dL per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Serum Cholesterol | Partner: 6mo-12mo | -1.30 mg/dL per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Serum Cholesterol | Partner: 6mo-12mo | -3.11 mg/dL per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Serum Cholesterol | Survivor: Baseline-6mo | 2.74 mg/dL per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Serum Cholesterol | Partner: Baseline-6mo | -2.18 mg/dL per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Serum Cholesterol | Survivor: 6mo-12mo | -0.71 mg/dL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Serum Cholesterol | Partner: 6mo-12mo | 0.85 mg/dL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Serum Cholesterol | Survivor: 6mo-12mo | 2.68 mg/dL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Serum Cholesterol | Partner: Baseline-6mo | -2.91 mg/dL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Serum Cholesterol | Survivor: Baseline-6mo | -6.45 mg/dL per 6 months |
Secondary
Cardiovascular Health: Serum Triglycerides
Measured by serum triglycerides.
Time frame: Baseline, 3, 6, and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Serum Triglycerides | Partner: Baseline-6mo | -4.53 mg/dL per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Serum Triglycerides | Survivor: 6mo-12mo | 4.79 mg/dL per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Serum Triglycerides | Partner: 6mo-12mo | -8.44 mg/dL per 6 months |
| Arm I (Supervised Exercise Together) | Cardiovascular Health: Serum Triglycerides | Survivor: Baseline-6mo | -9.86 mg/dL per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Serum Triglycerides | Survivor: 6mo-12mo | -0.15 mg/dL per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Serum Triglycerides | Partner: 6mo-12mo | -15.28 mg/dL per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Serum Triglycerides | Survivor: Baseline-6mo | 7.00 mg/dL per 6 months |
| Arm II (Supervised Exercise Separately) | Cardiovascular Health: Serum Triglycerides | Partner: Baseline-6mo | 11.13 mg/dL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Serum Triglycerides | Survivor: Baseline-6mo | -9.76 mg/dL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Serum Triglycerides | Partner: 6mo-12mo | 16.41 mg/dL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Serum Triglycerides | Partner: Baseline-6mo | 2.64 mg/dL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Cardiovascular Health: Serum Triglycerides | Survivor: 6mo-12mo | 12.02 mg/dL per 6 months |
Secondary
Depressive Symptoms: CES-D
Measured by the Center for Epidemiological Studies-Depression (CES-D) scale to determine the degree of depressive symptoms. Scores range from 0-60, with higher scores indicating more symptoms that occur at higher frequencies.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Depressive Symptoms: CES-D | Survivor: Baseline-6mo | -1.50 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Depressive Symptoms: CES-D | Survivor: 6mo-12mo | -0.10 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Depressive Symptoms: CES-D | Partner: Baseline-6mo | -1.41 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Depressive Symptoms: CES-D | Partner: 6mo-12mo | 1.07 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Depressive Symptoms: CES-D | Partner: 6mo-12mo | -0.29 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Depressive Symptoms: CES-D | Survivor: Baseline-6mo | -0.72 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Depressive Symptoms: CES-D | Partner: Baseline-6mo | -1.73 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Depressive Symptoms: CES-D | Survivor: 6mo-12mo | 0.26 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Depressive Symptoms: CES-D | Partner: 6mo-12mo | 0.83 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Depressive Symptoms: CES-D | Survivor: 6mo-12mo | -0.21 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Depressive Symptoms: CES-D | Partner: Baseline-6mo | -1.76 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Depressive Symptoms: CES-D | Survivor: Baseline-6mo | -1.10 Score on a scale per 6 months |
Secondary
Fear of Recurrence
Measured by the Fear of Recurrence scale to assess the amount of concern survivors have about their cancer returning in the future. Participants respond to 22 questions ranging from 1 (strongly agree) to 5 (strongly disagree). The possible range is 22-110. Higher scores reflect higher fear. Reported values reflect the estimated slope over 6-months.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are survivors only since this scale is cancer survivor specific.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Fear of Recurrence | Survivor: Baseline-6mo | -2.61 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Fear of Recurrence | Survivor: 6mo-12mo | -1.63 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Fear of Recurrence | Survivor: Baseline-6mo | -2.48 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Fear of Recurrence | Survivor: 6mo-12mo | -1.72 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Fear of Recurrence | Survivor: Baseline-6mo | -3.72 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Fear of Recurrence | Survivor: 6mo-12mo | -0.31 Score on a scale per 6 months |
Secondary
Inflammation-hsCRP
Measured by serum levels of high sensitivity C-reactive protein (hsCRP) obtained from a fasting blood sample.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Inflammation-hsCRP | Survivor: Baseline-6mo | -0.11 mg/L per 6 months |
| Arm I (Supervised Exercise Together) | Inflammation-hsCRP | Survivor: 6mo-12mo | -0.12 mg/L per 6 months |
| Arm I (Supervised Exercise Together) | Inflammation-hsCRP | Partner: Baseline-6mo | 0.01 mg/L per 6 months |
| Arm I (Supervised Exercise Together) | Inflammation-hsCRP | Partner: 6mo-12mo | -0.12 mg/L per 6 months |
| Arm II (Supervised Exercise Separately) | Inflammation-hsCRP | Partner: 6mo-12mo | -0.13 mg/L per 6 months |
| Arm II (Supervised Exercise Separately) | Inflammation-hsCRP | Survivor: Baseline-6mo | 0.09 mg/L per 6 months |
| Arm II (Supervised Exercise Separately) | Inflammation-hsCRP | Partner: Baseline-6mo | -0.11 mg/L per 6 months |
| Arm II (Supervised Exercise Separately) | Inflammation-hsCRP | Survivor: 6mo-12mo | -0.20 mg/L per 6 months |
| Arm III (Unsupervised Exercise Separately) | Inflammation-hsCRP | Partner: 6mo-12mo | -0.03 mg/L per 6 months |
| Arm III (Unsupervised Exercise Separately) | Inflammation-hsCRP | Survivor: 6mo-12mo | 0.13 mg/L per 6 months |
| Arm III (Unsupervised Exercise Separately) | Inflammation-hsCRP | Partner: Baseline-6mo | -0.04 mg/L per 6 months |
| Arm III (Unsupervised Exercise Separately) | Inflammation-hsCRP | Survivor: Baseline-6mo | -0.05 mg/L per 6 months |
Secondary
Inflammation-TNF Alpha
Measured by serum levels of tumor necrosis factor alpha (TNF alpha) obtained from a fasting blood sample.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Inflammation-TNF Alpha | Survivor: Baseline-6mo | -0.01 pg/mL per 6 months |
| Arm I (Supervised Exercise Together) | Inflammation-TNF Alpha | Partner: Baseline-6mo | -0.02 pg/mL per 6 months |
| Arm I (Supervised Exercise Together) | Inflammation-TNF Alpha | Partner: 6mo-12mo | 0.00 pg/mL per 6 months |
| Arm I (Supervised Exercise Together) | Inflammation-TNF Alpha | Survivor: 6mo-12mo | -0.01 pg/mL per 6 months |
| Arm II (Supervised Exercise Separately) | Inflammation-TNF Alpha | Survivor: Baseline-6mo | -0.02 pg/mL per 6 months |
| Arm II (Supervised Exercise Separately) | Inflammation-TNF Alpha | Survivor: 6mo-12mo | -0.02 pg/mL per 6 months |
| Arm II (Supervised Exercise Separately) | Inflammation-TNF Alpha | Partner: Baseline-6mo | -0.02 pg/mL per 6 months |
| Arm II (Supervised Exercise Separately) | Inflammation-TNF Alpha | Partner: 6mo-12mo | 0.00 pg/mL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Inflammation-TNF Alpha | Partner: Baseline-6mo | 0.00 pg/mL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Inflammation-TNF Alpha | Survivor: Baseline-6mo | -0.03 pg/mL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Inflammation-TNF Alpha | Survivor: 6mo-12mo | -0.01 pg/mL per 6 months |
| Arm III (Unsupervised Exercise Separately) | Inflammation-TNF Alpha | Partner: 6mo-12mo | 0.03 pg/mL per 6 months |
Secondary
Objective Physical Function
Measured by the Physical Performance Battery (PPB) to determine a person's ability to perform daily tasks independently. The PPB consists of 3 timed tests: 5 repeated chair stands, standing balance, and gait speed over 4 meters. Each test is scored 0 (unable) to 4 (completes without difficulty), based on quartiles of performance, then scores are summed. The possible range of scores is 0-12.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are total number of individuals (survivors + partners)
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Objective Physical Function | Survivor: 6mo-12mo | -0.03 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Objective Physical Function | Survivor: Baseline-6mo | 0.75 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Objective Physical Function | Partner: Baseline-6mo | 0.15 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Objective Physical Function | Partner: 6mo-12mo | 0.11 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Objective Physical Function | Partner: 6mo-12mo | -0.18 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Objective Physical Function | Partner: Baseline-6mo | 0.82 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Objective Physical Function | Survivor: Baseline-6mo | 0.86 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Objective Physical Function | Survivor: 6mo-12mo | -0.07 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Objective Physical Function | Survivor: Baseline-6mo | 0.73 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Objective Physical Function | Survivor: 6mo-12mo | -0.30 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Objective Physical Function | Partner: Baseline-6mo | 0.73 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Objective Physical Function | Partner: 6mo-12mo | -0.11 Score on a scale per 6 months |
Secondary
Quality of Life (QOL): QLQ-C30 - Emotional Functioning
Measures QOL in cancer patients including subscales of emotional functioning. Scores range from 0-100 for overall QOL and subscales where higher scores indicate better functioning.
Time frame: Baseline, 3, 6, 12 months
Population: Overall number of participants analyzed are survivors only since this scale is cancer survivor specific.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Quality of Life (QOL): QLQ-C30 - Emotional Functioning | Survivor: Baseline-6mo | 4.18 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Quality of Life (QOL): QLQ-C30 - Emotional Functioning | Survivor: 6mo-12mo | -0.34 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Quality of Life (QOL): QLQ-C30 - Emotional Functioning | Survivor: 6mo-12mo | -0.39 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Quality of Life (QOL): QLQ-C30 - Emotional Functioning | Survivor: Baseline-6mo | 1.82 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Quality of Life (QOL): QLQ-C30 - Emotional Functioning | Survivor: Baseline-6mo | 4.67 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Quality of Life (QOL): QLQ-C30 - Emotional Functioning | Survivor: 6mo-12mo | -1.99 Score on a scale per 6 months |
Secondary
Quality of Life (QOL): QLQ-C30 - Physical Functioning
Measures QOL in cancer patients including subscales of physical functioning. Scores range from 0-100 for overall QOL and subscales where higher scores indicate better functioning.
Time frame: Baseline, 3, 6 and 12 months
Population: Overall number of participants analyzed are survivors only since this scale is cancer survivor specific.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Quality of Life (QOL): QLQ-C30 - Physical Functioning | Survivor: Baseline-6mo | 2.12 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Quality of Life (QOL): QLQ-C30 - Physical Functioning | Survivor: 6mo-12mo | -1.44 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Quality of Life (QOL): QLQ-C30 - Physical Functioning | Survivor: Baseline-6mo | 1.23 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Quality of Life (QOL): QLQ-C30 - Physical Functioning | Survivor: 6mo-12mo | -0.30 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Quality of Life (QOL): QLQ-C30 - Physical Functioning | Survivor: Baseline-6mo | 1.26 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Quality of Life (QOL): QLQ-C30 - Physical Functioning | Survivor: 6mo-12mo | 1.74 Score on a scale per 6 months |
Secondary
Quality of Life (QOL): SF-36 Physical Function Subscale
The SF-36 measures quality of life using 8 subscales: perceived physical function, role limitations due to physical problems, social functioning, bodily pain, general mental health, role limitations due to emotional problems, vitality, and general health perceptions. All subscales have possible scores from 0-100, with items from each subscale averaged together. Low scores indicate worse physical functioning, while higher scores indicate better physical functioning.
Time frame: Baseline, 3, 6 and 12 months
Population: This measure had a significant amount of missing data for partners (due to a survey logic error) so the total sample size is reduced.
| Arm | Measure | Group | Value (MEAN) |
|---|---|---|---|
| Arm I (Supervised Exercise Together) | Quality of Life (QOL): SF-36 Physical Function Subscale | Partner: 6mo-12mo | -0.89 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Quality of Life (QOL): SF-36 Physical Function Subscale | Survivor: Baseline-6mo | 1.73 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Quality of Life (QOL): SF-36 Physical Function Subscale | Partner: Baseline-6mo | 1.81 Score on a scale per 6 months |
| Arm I (Supervised Exercise Together) | Quality of Life (QOL): SF-36 Physical Function Subscale | Survivor: 6mo-12mo | -0.76 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Quality of Life (QOL): SF-36 Physical Function Subscale | Partner: Baseline-6mo | 1.94 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Quality of Life (QOL): SF-36 Physical Function Subscale | Partner: 6mo-12mo | -0.04 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Quality of Life (QOL): SF-36 Physical Function Subscale | Survivor: 6mo-12mo | -0.56 Score on a scale per 6 months |
| Arm II (Supervised Exercise Separately) | Quality of Life (QOL): SF-36 Physical Function Subscale | Survivor: Baseline-6mo | 2.47 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Quality of Life (QOL): SF-36 Physical Function Subscale | Partner: 6mo-12mo | 1.02 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Quality of Life (QOL): SF-36 Physical Function Subscale | Survivor: 6mo-12mo | -0.81 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Quality of Life (QOL): SF-36 Physical Function Subscale | Partner: Baseline-6mo | 0.12 Score on a scale per 6 months |
| Arm III (Unsupervised Exercise Separately) | Quality of Life (QOL): SF-36 Physical Function Subscale | Survivor: Baseline-6mo | 0.96 Score on a scale per 6 months |